ProSciento to Present at the Annual World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease

ProSciento to Present at the Annual World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease

SAN DIEGO, November 18, 2014 – ProSciento, Inc., a clinical research organization (CRO) focused on diabetes and obesity, will present at the Annual World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease, taking place November 20-22 in Los Angeles. The presentation will take place on November 20 and is a ‘Meet the Expert’ session focused on the role of insulin resistance in the pathogenesis of type 2 diabetes and associated cardiometabolic disorders. The speaker, Prof. Andrew Krentz, is a key scientist at ProSciento, as well as a co-author and editor of the forthcoming textbook Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development.

Topics discussed during the session will include:

  • The role of insulin resistance in the pathogenesis of type 2 diabetes and associated cardiometabolic disorders and its importance as a  therapeutic target
  • Available insulin-sensitizing drugs and the prospects for novel agents currently in development
  • Strengths and limitations of established methods together with some recent advances in the assessment of insulin action

More information about the Annual World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease can be found at http://www.wcir.org.

For more information about ProSciento, please visit www.prosciento.com.

About ProSciento, Inc.

ProSciento is a metabolism-focused, full scope clinical R&D services provider, with a mission to advance the global development of novel therapeutics for diabetes, NASH and obesity. The company is widely recognized for quality and scientific excellence, an unparalleled methodological toolkit, and extensive experience with virtually all metabolic drug and device classes. Utilizing its scalable R&D services model – combining deep therapeutic area expertise, strategic planning, an unparalleled methodological tool kit, and operational execution from late preclinical to phase III readiness – ProSciento provides highly customizable services for its global client base in today’s rapidly evolving landscape of metabolic drug and device development. For more information, please visit www.prosciento.com.

For media inquiries, please contact:
Abby Devine
Senior Director, Corporate Communications, ProSciento, Inc.
Tel: +1 858 663-6148
abby.devine@prosciento.com

For business development inquires:
bd@prosciento.com

For clinical study enrollment inquires:
Tel: +1 (866) 308-7427
volunteer@prosciento.com